Open AccessEfficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial
Author(s) -
Junbo Ge,
Fan Wei-hu,
Jingmin Zhou,
Shi H,
Fusui Ji,
Yang Wu,
Yang Zhao,
Jun Qian,
Yinji Jin,
Yingwu Liu,
Sheng-Huang Wang,
Shenghu He,
Ping Yang,
Jie Wu,
Feng Hwa Lu,
Zi-Shan Hou
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001257
Subject(s) - medicine , myocardial infarction , coronary artery disease , angina , placebo , unstable angina , stroke (engine) , randomized controlled trial , adverse effect , clinical endpoint , odds ratio , cardiology , aspirin , mace , percutaneous coronary intervention , mechanical engineering , alternative medicine , pathology , engineering
The Shexiang Baoxin Pill (MUSKARDIA) has been used for treating coronary artery disease (CAD) and angina for more than 30 years in China. Nevertheless, methodologically sound trials on the use of MUSKARDIA in CAD patients are scarce. The aim of the study is to determine the effects of MUSKARDIA as an add-on to optimal medical therapy (OMT) in patients with stable CAD.